Date Filed | Type | Description |
10/11/2023 |
8-K
| Quarterly results |
08/16/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
08/14/2023 |
8-K
| Quarterly results |
07/26/2023 |
8-K
| Quarterly results |
06/07/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
06/07/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
06/07/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
05/12/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
04/14/2023 |
8-K
| Quarterly results |
03/28/2023 |
8-K
| Quarterly results |
03/22/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
03/22/2023 |
8-K
| Quarterly results |
03/13/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
02/14/2023 |
SC 13G/A
| Mack Anthony P. reports a 26.1% stake in VIRPAX PHARMACEUTICALS, Inc. |
01/26/2023 |
SC 13G/A
| Kepos Capital LP reports a 0% stake in Virpax Pharmaceuticals, Inc. |
01/10/2023 |
SC 13G/A
| SABBY MANAGEMENT, LLC reports a 8.4% stake in Virpax Pharmaceuticals, Inc. |
12/29/2022 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
11/22/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
11/09/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
11/09/2022 |
8-K
| Quarterly results |
10/19/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
10/07/2022 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
08/15/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
08/15/2022 |
8-K
| Quarterly results |
07/25/2022 |
8-K
| Quarterly results |
06/27/2022 |
8-K
| Quarterly results |
06/21/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
06/15/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
06/15/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
05/16/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
05/16/2022 |
8-K
| Quarterly results |
05/06/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
03/31/2022 |
8-K
| Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits I... |
|